Chimeric Bispecific Antibody to Treat Kidney Cancer
Author Information
Author(s): RM Luiten, LR Coney, GJ Fleuren, SO Warnaarl, SV Litvinov
Primary Institution: Department of Pathology, University of Leiden
Hypothesis
The chimeric bispecific G250/anti-CD3 monoclonal antibody can effectively target and lyse renal cell carcinoma cells.
Conclusion
The chimeric bispecific G250/anti-CD3 MAb can induce lysis of renal cell carcinoma cells by human T cells at very low concentrations.
Supporting Evidence
- The chimeric bispecific antibody was capable of mediating lysis of RCC cell lines by human T cells.
- Lysis was specific for target cells expressing the G250 antigen.
- The chimeric bispecific G250/anti-CD3 MAb was effective at concentrations as low as 0.01 pg/ml.
Takeaway
Scientists created a special antibody that can help the body's immune cells attack kidney cancer cells better.
Methodology
The study involved generating a chimeric bispecific antibody and testing its ability to mediate lysis of renal cell carcinoma cells in vitro using human T cells.
Limitations
The study primarily involved in vitro experiments, and the effectiveness in vivo remains to be fully evaluated.
Statistical Information
P-Value
p<0.0001
Statistical Significance
p<0.0001
Want to read the original?
Access the complete publication on the publisher's website